Daniel M Halperin

List of Publications by Citations

47 papers	2,540 citations	14 h-index	50 g-index
53 ext. papers	3,283 ext. citations	5.9 avg, IF	5 L-index

#	Paper	IF	Citations
47	Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. *JAMA Oncology*, **2017**, 3, 1335-1342	13.4	1391
46	Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 12351-6	11.5	519
45	Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. *Lancet Oncology, The*, **2017**, 18, 525-534	21.7	185
44	Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. *Lancet Oncology, The*, **2015**, 16, 695-703	21.7	94
43	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. *Pancreas*, **2020**, 49, 863-881	2.6	35
42	Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis. *Oncotarget*, **2017**, 8, 99541-99551	3.3	31
41	Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. *Journal of Gastrointestinal Surgery*, **2017**, 21, 155-163	3.3	27
40	Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. *Endocrine-Related Cancer*, **2015**, 22, 431-41	5.7	23
39	A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors. *Annual Review of Medicine*, **2015**, 66, 1-16	17.4	23
38	Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. *Annals of Surgical Oncology*, **2018**, 25, 1709-1715	3.1	21
37	Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter?. *Current Oncology Reports*, **2014**, 16, 366	6.3	19
36	Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. *Oncologist*, **2017**, 22, 1451-1462	5.7	17
35	Management of Diarrhea in Patients With Carcinoid Syndrome. *Pancreas*, **2019**, 48, 961-972	2.6	17
34	Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms. *Endocrine-Related Cancer*, **2021**,	5.7	14
33	A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. *BMC Cancer*, **2014**, 14, 561	4.8	13
32	Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. *Cancer Discovery*, **2021**, 11, 2738-2747	24.4	11
31	Management of pancreatic neuroendocrine tumors. *Gastroenterology Clinics of North America*, **2012** , 41, 119-31	4.4	10

30	Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study. *Scientific Reports*, **2018**, 8, 16863	4.9	8
29	Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors. *Annals of Oncology*, **2017**, 28, 1582-1589	10.3	7
28	Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome. *BMC Cancer*, **2019**, 19, 274	4.8	7
27	Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1?. *Clinical Endocrinology*, **2017**, 86, 791-797	3.4	4
26	Direct costs of carcinoid syndrome diarrhea among adults in the United States. *World Journal of Gastroenterology*, **2019**, 25, 6857-6865	5.6	4
25	Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. *Pancreas*, **2020**, 49, 1123-1130	2.6	4
24	Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. *Clinical Colorectal Cancer*, **2020**, 19, e117-e123	3.8	4
23	Update on management of midgut neuroendocrine tumors. *International Journal of Endocrine Oncology*, **2016**, 3, 175-189	0.3	4
22	A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. *Pancreas*, **2019**, 48, 381-386	2.6	4
21	[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. *Future Oncology*, **2016**, 12, 313-21	3.6	3
20	Clinical Trial Design in Neuroendocrine Tumors. *Hematology/Oncology Clinics of North America*, **2016**, 30, 209-17	3.1	3
19	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directives. *Endocrine-Related Cancer*, **2020**, 27, T9-T25	5.7	3
18	Loss of Menin Expression by Immunohistochemistry in Pancreatic Neuroendocrine Tumors: Comparison Between Primary and Metastatic Tumors. *Pancreas*, **2019**, 48, 510-513	2.6	3
17	Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. *Expert Review of Pharmacoeconomics and Outcomes Research*, **2020**, 20, 507-511	2.2	3
16	Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study. *Medicine (United States)*, **2018**, 97, e13390	1.8	3
15	Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials. *Journal of Clinical Oncology*, **2015**, 33, 2914-9	2.2	2
14	Future Directions in the Biology of Neuroendocrine Tumors. *Pancreas*, **2016**, 45, 783-5	2.6	2
13	Incidence and prognosis of carcinoid syndrome: hormones or tumour burden? - AuthorsUreply. *Lancet Oncology, The*, **2017**, 18, e300	21.7	1

12	Development of a drug-device combination for fluorescence-guided surgery in neuroendocrine tumors. *Journal of Biomedical Optics*, **2020**, 25,	3.5	1
11	Safety and interim results from a phase II, single-arm study of atezolizumab and bevacizumab in Merkel cell carcinoma (MCC).. *Journal of Clinical Oncology*, **2019**, 37, e21006-e21006	2.2	1
10	Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. *JAMA Network Open*, **2021**, 4, e2131744	10.4	1
9	Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. *Neuroendocrinology*, **2021**, 111, 850-862	5.6	1
8	A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e4969-e4980	5.6	1
7	FAS and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. *Neuroendocrinology*, **2021**,	5.6	1
6	Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology. *BMC Medical Research Methodology*, **2018**, 18, 169	4.7	1
5	Operationalizing Virtual Trials in Oncology-From Aspiration to Action. *JCO Clinical Cancer Informatics*, **2021**, 5, 953-957	5.2	1
4	Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists.. *Abdominal Radiology*, **2022**, 1	3	1
3	A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. *Pharmacoeconomics*, **2021**, 39, 1271-1297	4.4	0
2	Incidence of Lymph Node Metastases and Impact of Radical Surgery for Duodenal Neuroendocrine Tumors. *Journal of Surgical Research*, **2021**, 268, 419-431	2.5	
1	Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis.. *Annals of Surgical Oncology*, **2022**, 29, 3072	3.1	